## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 7.1% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($185.67)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Charles River Laboratories stock hits 52-week high at 200.51 USD**
- Source: Investing.com | 20251215T145604 | Bullish | Relevance: 100%
- Charles River Laboratories (CRL) stock has reached a new 52-week high of $200.51, reflecting a 1.56% increase over the past year and a 29.16% return over the last six months. This surge is underpinned by strong investor confidence, analyst expectations of profitability for the current year with a forecasted EPS of $10.34, and strategic share buybacks by management. Recent developments include multiple analyst upgrades and a concluded SEC investigation without enforcement action, contributing to its positive trajectory.

**2. JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating**
- Source: marketscreener.com | 20251215T140303 | Somewhat-Bullish | Relevance: 100%
- JPMorgan has adjusted its price target for Charles River Laboratories International (NYSE: CRL) to $190, an increase from the previous $165, while maintaining a Neutral rating on the stock. This update reflects the firm's revised outlook for the company, following other analyst activities for CRL. The article also provides recent news headlines and stock performance data for Charles River Laboratories International.

**3. Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High After Analyst Upgrade**
- Source: MarketBeat | 20251215T153005 | Bullish | Relevance: 100%
- Charles River Laboratories International (NYSE:CRL) achieved a new 52-week high after Bank of America upgraded its rating from neutral to buy, setting a $225 price target. The stock hit $202 and last traded around $198, following a previous close of $193.03. Analysts have a "Moderate Buy" consensus rating for CRL, with a target price of $192.29, and institutional investors hold a significant 98.91% stake in the company.

**4. Charles River Laboratories International (NYSE:CRL) Upgraded at Bank of America**
- Source: MarketBeat | 20251215T145504 | Bullish | Relevance: 100%
- Bank of America has upgraded Charles River Laboratories International (NYSE:CRL) from "neutral" to "buy," setting a $225 price objective that implies a 13.59% upside. This upgrade comes as the company continues to beat quarterly earnings estimates, with its stock currently trading near its 52-week high. Analysts collectively maintain a "Moderate Buy" consensus rating with a target price of $192.29, despite mixed individual price changes from other research firms.

**5. Charles River Labs stock rating upgraded by BofA on early research exposure**
- Source: Investing.com | 20251215T131703 | Bullish | Relevance: 100%
- BofA Securities has upgraded Charles River Labs (NYSE:CRL) from Neutral to Buy, increasing its price target to $225.00 due to the company's strong position in early-stage pharmaceutical R&D and progress in cost-cutting. This upgrade represents a significant upside from its current trading price, with the stock nearing its 52-week high. The decision is also supported by the company's ongoing strategic review and recent positive earnings, despite some investor concerns about organic revenue decline.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 18.1x stretched relative to 7% growth. Analyst sentiment positive (2 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 1.64 |
| 52W Range | $91.86 - $200.51 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 18.1 |
| Current P/E | 19.3 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.9% to 7.1% (+5.3% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (7.1% > 6.0%), caution on chasing. MRS_5 at 4.1% confirms short-term momentum alignment. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.14), confirming momentum. RSI overbought at 71, risk of mean reversion. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 7.14% (CS: 96) | Strong |
| RSI_14 | 71.3 | Overbought |
| MACD Histogram | 2.14 | Bullish |
| vs SMA20 | 1.107x | Above |
| vs SMA50 | 1.115x | Above |
| vs SMA200 | 1.264x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $198.15
- **Stop Loss:** $185.67 (6.3% risk)
- **Target:** $210.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 96
- **Position Value:** $19,022.40
- **Portfolio %:** 19.02%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*